Our publications

In order to grow and develop as people, as professionals, and as a company, we find it essential to contribute to the academic progress. Below we provide links to posters and publications by Pharmetheus affiliates in chronological order. Please note that access to some publications may require a subscription.


Friberg Hietala S., Manolis E., Musuamba F. T., (2017) A Regulatory View on Dose Finding Studies and on the Value of Dose-Exposure-Response Analysis. In O’Quigley J., Iasonos A., Bornkamp B., (Eds.), Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Boca Raton FL:CRC Press

Magnusson M. O.Samtani M. N. Plan E. L., Jonsson E. N.Rossenu S., Vermeulen A., Russu A. Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data. (2017) CNS Drugs.

Dosne AG., Bergstrand M., Karlsson M. O., An Automated Sampling Importance Resampling Procedure for Estimating Parameter Uncertainty. (2017) Clin. Pharmacol. Ther., 101: S5–S99

Röshammar D., Bergstrand M., Andersson T., Storey R.F., Hamrén B. Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
. (2017) Int J Clin Pharmacol Ther. Jan 30.

Nguyen T., Mouksassi M.-S., Holford N., Al-Huniti N., Freedman I., Hooker A., John J., Karlsson M., Mould D., Pérez Ruixo J., Plan E. L., Savic R., van Hasselt J., Weber B., Zhou C., Comets E., Mentré F. for the Model Evaluation Group of the International Society of Pharmacometrics (ISoP) Best Practice Committee, Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics. (2017) CPT Pharmacometrics Syst. Pharmacol.

Röshammar D., Nyberg J., Andersson T., Stanski D., Storey R. F., Hamrén B. Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction. (2016) J Clin Pharmacol. Nov.

Magnusson M. O., Samtani M.N., Plan E.L., Jonsson E. N., Rossenu S., Vermeulen A., Russu A. Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia. (2016) Clin Pharmacokinet., 56: 421

van Schaick E., Benninga M. A., Levine A., Magnusson M. O., Troy S. Development of a population pharmacokinetic model of prucalopride in children with functional constipation. (2016) Pharma Res Per, 4(4), e00236. 

Magnusson M. O. Application of a multi-criteria decision analysis model in the dose selection of combination therapy for overactive bladder. (2016) WCoP, Talk: Symposium 5, Pharmacometric approaches to optimize dose selection Abstr 125.

Jonsson E. N., Xie R., Marshall S. F., Arends R. H. Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain. (2016) Br J Clin Pharmacol. Apr;81(4):688-99

Jonsson E. N., Nyberg J., Häggström J., Lifecycle Auxology & Neurocognitive Development team, representing the Healthy Birth, Growth and Development knowledge integration (HBGDki) community. Determinants for physical growth patterns in low- and middle-income countries. (2016) PAGE 25 Abstr 5844, Talk: Growth.

Magnusson M. O., Plan E. L., Remy A., König M., Aigner S., Braun, V., Zipp D., Zhou X., Wolter R., Schüttrumpf J., Wartenberg-Demand A., Dälken B., Rharbaoui F. Population PKPD Analysis of CD4 and ACR Response after SC Administration of Tregalizumab to Patients with Rheumatoid Arthritis. (2016) PAGE 25 Abstr 5708.

Hamberg AK., Hellman J., Dahlberg J., Jonsson E. N., Wadelius M. A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children. (2015) BMC Med Inform Decis Mak. Feb 7;15:7

Khariton T., Jonsson E. N., Bergstrand M., Carrothers T. J., Ghahramani P. Population Pharmacokinetic (PPK) Modeling of Vilazodone in Adolescent Patients with Major Depressive Disorder (MDD). (2015) J Pharmacokinet Pharmacodyn 42(Suppl 1): 11

Khariton T., Jonsson E. N., Bergstrand M., Carrothers T. J., Ghahramani P. PKPD Modeling of Vilazodone (VLZ) in Adult Patients with Generalized Anxiety Disorder (GAD). (2015) J Pharmacokinet Pharmacodyn 42(Suppl 1): 11

Magnusson M. O., Samtani M. N., Plan E. L., Jonsson E. N., Rossenu S., Vermeulen A. Population Pharmacokinetic Simulations of Two Paliperidone Palmitate Formulations. (2015) PAGE 24 Abstr 3643.

Magnusson M. O., Samtani M. N., Plan E. L., Jonsson E. N., Rossenu S., Vermeulen A. Population Pharmacokinetic Modeling of Paliperidone Palmitate 3-Month Formulation. (2015) PAGE 24 Abstr 3408.

Plan E. L. Modeling and simulation of count data. (2014) CPT Pharmacometrics Syst. Pharmacol. 3, e129.

Khariton T., Bergstrand M., Plan E. L., Ghahramani P. A Population PKPD Model for Changes in Sexual Function Questionnaire (CSFQ) in Patients with Major Depressive Disorder (MDD) Treated with Vilazodone or Placebo. (2014)  J Pharmacokinet Pharmacodyn 41(Suppl 1): 7

Hamberg A. K., Wadelius M., Friberg L. E., Biss T. T., Kamali F., Jonsson E. N. Characterizing variability in warfarin dose requirements in children using modelling and simulation. (2014) Br J Clin Pharmacol. Jul;78(1):158-69

Magnusson M. O., Jonsson E. N., Chen C. L., Carrothers T., Ghahramani P. A Population PK/PD Analysis of Nebivolol and Valsartan Combination Therapy. (2014) PAGE 23 Abstr 3162.

Jonsson E. N., Magnusson M. O., Chen C. L., Carrothers T., Ghahramani P. A Population PK Analysis of Nebivolol and Valsartan in Combination Therapy. (2014) PAGE 23 Abstr 3150.

Justin J. Wilkins J. J., Jonsson E. N. Reproducible Pharmacometrics.  (2013) PAGE 22 Abstr 2774 Oral: Tutorial